Cargando…

Syk Activation in Circulating and Tissue Innate Immune Cells in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

OBJECTIVE: Syk is a cytoplasmic protein tyrosine kinase that plays a role in signaling via B cell and Fc receptors (FcR). FcR engagement and signaling via Syk is thought to be important in antineutrophil cytoplasm antibody (ANCA) IgG–mediated neutrophil activation. This study was undertaken to inves...

Descripción completa

Detalles Bibliográficos
Autores principales:	Prendecki, Maria, Gulati, Kavita, Pisacano, Noelle, Pinheiro, Damilola, Bhatt, Tejal, Mawhin, Marie‐Anne, Toulza, Frederic, Masuda, Esteban S., Cowburn, Andrew, Lodge, Katharine M., Tam, Frederick W. K., Roufosse, Candice, Pusey, Charles D., McAdoo, Stephen P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wiley Periodicals, Inc. 2022
Materias:	Vasculitis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10099805/ https://www.ncbi.nlm.nih.gov/pubmed/36428281 http://dx.doi.org/10.1002/art.42321

Ejemplares similares

Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis
por: Merkel, Peter A., et al.
Publicado: (2017)

Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: A Randomized Controlled Study
por: Jayne, David, et al.
Publicado: (2019)

Efficacy of mycophenolate mofetil as a remission induction therapy in antineutrophil cytoplasmic antibody-associated vasculitis—a meta-analysis
por: Kuzuya, Kentaro, et al.
Publicado: (2020)

Association of Pulmonary Hemorrhage, Positive Proteinase 3, and Urinary Red Blood Cell Casts With Venous Thromboembolism in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
por: Kronbichler, Andreas, et al.
Publicado: (2019)

Risk Factors for Severe Outcomes in Patients With Systemic Vasculitis and COVID‐19: A Binational, Registry‐Based Cohort Study
por: Rutherford, Matthew A., et al.
Publicado: (2021)

Diagnostic significance of antineutrophil cytoplasmic antibody (ANCA) titres: a retrospective case-control study
por: Merindol, Julie, et al.
Publicado: (2023)

Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis
por: Smith, Rona M, et al.
Publicado: (2020)

Daratumumab for the treatment of refractory ANCA-associated vasculitis
por: Ostendorf, Lennard, et al.
Publicado: (2023)

Immune checkpoint inhibitors as potential triggers for ANCA vasculitis
por: Aqeel, Faten, et al.
Publicado: (2022)

Risk factors for serious infections in ANCA-associated vasculitis
por: Odler, Balazs, et al.
Publicado: (2023)

Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial
por: Smith, Rona M, et al.
Publicado: (2023)

Phosphatidylinositol 3‐Kinase δ Deficiency Protects From Antimyeloperoxidase Vasculitis
por: Flórez‐Barrós, Fernanda, et al.
Publicado: (2022)

Outcomes of COVID-19 in patients with ANCA-associated vasculitis receiving avacopan
por: Aqeel, Faten, et al.
Publicado: (2023)

Long-term efficacy and safety of tocilizumab in giant cell arteritis and large vessel vasculitis
por: Evans, Jobie, et al.
Publicado: (2016)

Vessel inflammation and morphological changes in patients with large vessel vasculitis: a retrospective study
por: Besutti, Giulia, et al.
Publicado: (2022)

Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts
por: Yates, Max, et al.
Publicado: (2017)

T-lymphocyte in ANCA-associated vasculitis: what do we know? A pathophysiological and therapeutic approach
por: Martinez Valenzuela, Laura, et al.
Publicado: (2019)

Long-term patient survival in a Swedish population-based cohort of patients with ANCA-associated vasculitis
por: Heijl, Caroline, et al.
Publicado: (2017)

ANCA-associated renal vasculitis is associated with rurality but not seasonality or deprivation in a complete national cohort study
por: Aiyegbusi, Oshorenua, et al.
Publicado: (2021)

VEXAS Syndrome: A Case Series From a Single‐Center Cohort of Italian Patients With Vasculitis
por: Muratore, Francesco, et al.
Publicado: (2022)

Spleen tyrosine kinase inhibition is an effective treatment for established vasculitis in a pre-clinical model
por: McAdoo, Stephen P., et al.
Publicado: (2020)

Prevalence and risk factors of osteonecrosis of the femoral head in patients with ANCA-associated vasculitis: a multicentre cohort study
por: Mimura, Norihiro, et al.
Publicado: (2023)

Comparative study of granulomatosis with polyangiitis subsets according to ANCA status: data from the French Vasculitis Study Group Registry
por: Puéchal, Xavier, et al.
Publicado: (2022)

Influence of the EULAR recommendations for the use of imaging in large vessel vasculitis in the diagnosis of giant cell arteritis: results of the ARTESER register
por: De Miguel, Eugenio, et al.
Publicado: (2022)

Risk of relapse of ANCA-associated vasculitis among patients homozygous for the proteinase 3 gene Val119Ile polymorphism
por: Casal Moura, Marta, et al.
Publicado: (2023)

Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis
por: Monti, Sara, et al.
Publicado: (2019)

Management of Takayasu arteritis: a systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis
por: Águeda, Ana F, et al.
Publicado: (2019)

Prevalence and distribution of vascular calcifications at CT scan in patients with and without large vessel vasculitis: a matched cross-sectional study
por: Besutti, Giulia, et al.
Publicado: (2023)

Association between different infection profiles and one-year outcomes in ANCA-associated vasculitis: a retrospective study with monthly infection screening
por: Xu, Tingting, et al.
Publicado: (2022)

Definitions and reliability assessment of elementary ultrasound lesions in giant cell arteritis: a study from the OMERACT Large Vessel Vasculitis Ultrasound Working Group
por: Chrysidis, Stavros, et al.
Publicado: (2018)

Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (AAV): part 1—treatment of granulomatosis with polyangiitis and microscopic polyangiitis
por: Schirmer, Jan Henrik, et al.
Publicado: (2023)

Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (AAV): Part 2 - Treatment of eosinophilic granulomatosis with polyangiitis and diagnosis and general management of AAV
por: Sanchez-Alamo, Beatriz, et al.
Publicado: (2023)

Anti–glomerular basement membrane disease during the COVID-19 pandemic
por: Prendecki, Maria, et al.
Publicado: (2020)

Phase IIa Global Study Evaluating Rituximab for the Treatment of Pediatric Patients With Granulomatosis With Polyangiitis or Microscopic Polyangiitis
por: Brogan, Paul, et al.
Publicado: (2021)

Seasonal variations in the onset of positive and negative renal ANCA-associated vasculitis in Spain
por: Draibe, Juliana, et al.
Publicado: (2018)

Tocilizumab is effective against polymyalgia rheumatica: experience in 13 intractable cases
por: Izumi, Keisuke, et al.
Publicado: (2015)

Accuracy of musculoskeletal imaging for the diagnosis of polymyalgia rheumatica: systematic review
por: Mackie, Sarah Louise, et al.
Publicado: (2015)

PTPN22 R620W minor allele is a genetic risk factor for giant cell arteritis
por: Lester, Susan, et al.
Publicado: (2016)

Balancing on the edge: implications of a UK national audit of the use of BSR-BHPR guidelines for the diagnosis and management of polymyalgia rheumatica
por: Das, Parthajit, et al.
Publicado: (2015)

Geo-epidemiology of temporal artery biopsy-positive giant cell arteritis in Australia and New Zealand: is there a seasonal influence?
por: De Smit, Elisabeth, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_rpf205mnv363m5t5a859h4cst8